1. Home
  2. QSI vs ALLO Comparison

QSI vs ALLO Comparison

Compare QSI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QSI
  • ALLO
  • Stock Information
  • Founded
  • QSI 2013
  • ALLO 2017
  • Country
  • QSI United States
  • ALLO United States
  • Employees
  • QSI N/A
  • ALLO N/A
  • Industry
  • QSI Biotechnology: Pharmaceutical Preparations
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • QSI Health Care
  • ALLO Health Care
  • Exchange
  • QSI Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • QSI 334.9M
  • ALLO 363.1M
  • IPO Year
  • QSI N/A
  • ALLO 2018
  • Fundamental
  • Price
  • QSI $1.93
  • ALLO $1.50
  • Analyst Decision
  • QSI Strong Buy
  • ALLO Strong Buy
  • Analyst Count
  • QSI 3
  • ALLO 9
  • Target Price
  • QSI $2.38
  • ALLO $8.44
  • AVG Volume (30 Days)
  • QSI 8.0M
  • ALLO 3.6M
  • Earning Date
  • QSI 08-05-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • QSI N/A
  • ALLO N/A
  • EPS Growth
  • QSI N/A
  • ALLO N/A
  • EPS
  • QSI N/A
  • ALLO N/A
  • Revenue
  • QSI $3,443,000.00
  • ALLO N/A
  • Revenue This Year
  • QSI $77.57
  • ALLO N/A
  • Revenue Next Year
  • QSI $251.34
  • ALLO $199.63
  • P/E Ratio
  • QSI N/A
  • ALLO N/A
  • Revenue Growth
  • QSI 167.94
  • ALLO N/A
  • 52 Week Low
  • QSI $0.61
  • ALLO $0.86
  • 52 Week High
  • QSI $5.77
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • QSI 56.01
  • ALLO 62.31
  • Support Level
  • QSI $1.68
  • ALLO $1.21
  • Resistance Level
  • QSI $1.99
  • ALLO $1.31
  • Average True Range (ATR)
  • QSI 0.11
  • ALLO 0.11
  • MACD
  • QSI 0.01
  • ALLO 0.04
  • Stochastic Oscillator
  • QSI 81.25
  • ALLO 63.46

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: